NEW
YORK, July 15, 2024 /PRNewswire/ -- The global
sciatica treatment market size is estimated to grow by
USD 3.08 billion from 2023-2027,
according to Technavio. The market is estimated to grow at a CAGR
of 4.83% during the forecast period. Rising awareness
about sciatica is driving market growth, with a trend
towards development of clonidine micropellet epidural
injections. However, lack of approved treatments poses a
challenge. Key market players include Amneal Pharmaceuticals Inc.,
Apotex Inc., Aurobindo Pharma Ltd., Bayer AG, Dr Reddys
Laboratories Ltd., Elam Pharma Pvt. Ltd., Fresenius SE and Co.
KGaA, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc,
Johnson and Johnson, KOLON LIFE SCIENCE, Lupin Ltd., Novartis AG,
Omega Laser Systems Ltd., Ozone Pharmaceuticals Ltd., Pfizer Inc.,
Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical
Industries Ltd., and Viatris Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2023-2027
|
Base Year
|
2022
|
Historic
Data
|
2017 - 2021
|
Segment
Covered
|
End-user (Hospital,
Clinics, and Others), Product (Non-surgical treatment and Surgical
treatment), and Geography (North America, Europe, Asia, and Rest of
World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Amneal Pharmaceuticals
Inc., Apotex Inc., Aurobindo Pharma Ltd., Bayer AG, Dr Reddys
Laboratories Ltd., Elam Pharma Pvt. Ltd., Fresenius SE and Co.
KGaA, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc,
Johnson and Johnson, KOLON LIFE SCIENCE, Lupin Ltd., Novartis AG,
Omega Laser Systems Ltd., Ozone Pharmaceuticals Ltd., Pfizer Inc.,
Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical
Industries Ltd., and Viatris Inc.
|
Key Market Trends Fueling Growth
The sciatica treatment market is witnessing innovation with the
development of micropellet technology-based nonsteroidal epidural
injections. Currently, no FDA-approved steroids exist for sciatica
treatment, and off-label steroid preparations have limitations due
to associated side effects. Sollis Therapeutics is leading this
innovation with a Phase III clinical trial on clonidine
micropellets for sciatica pain relief in adults. This technology
enables targeted delivery of medication to affected nerves,
potentially improving safety and efficacy compared to steroidal
injections. As a result, micropellet-based medications are poised
to enter the market and contribute significantly to the sciatica
treatment market's growth during the forecast period.
The Sciatica Treatment Market is witnessing significant growth
due to the rising prevalence of lower back pain, buttocks, and legs
caused by irritation or compression of the sciatic nerve. According
to statistics, an estimated 40% of people will experience sciatica
symptoms at some point in their lives. Treatment options include
therapy, surgery, medication, and home care. Common causes of
sciatica include injury, nerves irritation, tumors, and age-related
changes. Complications from sciatica surgery can include bleeding
and infections. The pain management industry is seeing a trend
towards non-surgical treatments such as physical therapy and
chiropractic devices. In the medication category, pain killers and
anesthetics are commonly prescribed. Home care is also becoming
increasingly popular, especially for those with chronic sciatica.
Hospitals offer specialized care for severe cases. Risk factors for
sciatica include obesity, occupations that require prolonged
sitting, diabetes, osteoarthritis, and spondylolisthesis.
Age-related changes can also lead to sciatica symptoms. It's
important to note that while most cases of sciatica improve with
treatment, there is a risk of complications such as internal
bleeding and nerve damage.
Discover 360° analysis of this market. For
complete information, schedule your consultation- Book
Here!
Market Challenges
- Sciatica is a painful condition characterized by radiating pain
along the sciatic nerve. Common treatment approaches
include epidural corticosteroid injections, physiotherapy, and
bracing. These methods alleviate symptoms for most patients.
However, there's no approved cure for sciatica. Pain relief
medications like NSAIDs and analgesics are available for
symptomatic treatment. Surgery, involving lamina removal, is an
option for persistent pain. Market growth may be hindered due to
the absence of a definitive treatment for sciatica, as surgical
relief isn't guaranteed for all patients.
- The sciatica treatment market caters to individuals
experiencing pain caused by compression or irritation of the
sciatic nerve, which runs from the lower spine to the hips,
buttocks, and legs. Key challenges include an aging population with
increased incidence of age-related changes, obesity, and
occupations involving prolonged sitting. Other factors include
conditions like diabetes, osteoarthritis, spondylolisthesis,
spinal stenosis, and degenerative disk disease. Acute and chronic
sciatica require different treatment approaches. NSAIDs and
analgesics offer short-term relief for acute cases, while steroids,
antidepressants, and anticonvulsants are used for chronic sciatica.
The market includes production facilities, supply chain, and
pharmaceutical manufacturing. Safety and efficacy are crucial in
clinical trials for new treatments, addressing symptoms such as
lower back pain, stiffness, pain, burning sensation, and bone
spurs. The healthcare industry seeks effective and safe medication
to alleviate sciatica symptoms for its growing patient base.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This sciatica treatment market report extensively covers market
segmentation by
- End-user
- 1.1 Hospital
- 1.2 Clinics
- 1.3 Others
- Product
- 2.1 Non-surgical treatment
- 2.2 Surgical treatment
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Hospital- The global sciatica treatment market
in 2023 was dominated by hospitals as the largest end-users due to
the high volume of sciatica treatments performed there. Hospitals
serve as primary locations for sciatica treatments and patient
care. Common surgical procedures for sciatica include
microdiscectomy and laminectomy. Microdiscectomy addresses
herniated discs or bone spurs to alleviate pressure on the sciatic
nerve. The rising number of sciatica cases worldwide, estimated to
reach 843 million by 2050 according to WHO, is driving hospital
visits for sciatica treatments, fueling market growth.
For more information on market segmentation with geographical
analysis including forecast (2023-2027) and historic data (2017 -
2021) - Download a Sample Report
Learn and explore more about Technavio's in-depth research
reports
Chondrosarcoma is a rare type of cancer that forms in the
cartilage cells of bones, most commonly affecting the pelvis,
femur, and shoulder. It predominantly occurs in adults and is
characterized by its resistance to chemotherapy and radiation.
Early diagnosis is critical, with surgical removal being the
primary treatment option. Advances in imaging and surgical
techniques have improved patient outcomes, but the prognosis varies
depending on the tumor's grade and location. Ongoing research aims
to develop targeted therapies to enhance treatment effectiveness
for this challenging malignancy.
Research Analysis
The sciatic nerve, the longest and widest nerve in the human
body, runs from the lower spine, through the hips, and down the
legs, supplying sensation to the buttocks, legs, and feet. Sciatica
refers to the condition where this nerve becomes compressed or
irritated, leading to symptoms such as lower back pain, hip pain,
leg pain, and a burning sensation. Age-related changes, obesity,
occupations involving prolonged sitting, diabetes, osteoarthritis,
spondylolisthesis, and spinal stenosis are common causes of
sciatica. The incidence of sciatica increases with age and affects
millions worldwide. Healthcare providers offer various treatments,
including medication, physical therapy, and surgery, to provide
relief from sciatic nerve pain. The efficacy and safety of these
treatments depend on individual cases and underlying causes.
Symptoms may vary from mild to severe, causing stiffness, pain, and
discomfort, impacting daily activities.
Market Research Overview
The sciatica treatment market refers to the production and
supply of various therapies and medications aimed at providing
relief from sciatica, a condition characterized by pain, burning
sensation, and numbness along the sciatic nerve, which runs from
the lower spine to the hips, buttocks, and legs. Causes of sciatica
include age-related changes, obesity, occupations involving
prolonged sitting, diabetes, osteoarthritis, spondylolisthesis,
spinal stenosis, degenerative disk disease, and injuries. Symptoms
include lower back pain, stiffness, and pain or tingling in the
legs and hips. Treatment options include NSAIDs, analgesics,
steroids, antidepressants, and anticonvulsants, which can be
obtained from hospital pharmacies, clinics, or through home care.
The market includes production facilities and the supply chain
involved in pharmaceutical manufacturing. Acute and chronic
sciatica require different treatment approaches, with surgery being
a last resort due to potential complications such as internal
bleeding and infections. The geriatric population, with its higher
prevalence of chronic back pain, is a significant market segment.
The sciatica treatment market continues to evolve with ongoing
clinical trial programs and the development of new therapies,
including physical therapy and chiropractic devices, to improve
efficacy and safety.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- End-user
-
- Product
-
- Non-surgical Treatment
- Surgical Treatment
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sciatica-treatment-market-size-is-set-to-grow-by-usd-3-08-billion-from-2023-2027--rising-awareness-about-sciatica-to-boost-the-market-growth-technavio-302195992.html
SOURCE Technavio